Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00379613
Status:
COMPLETED
Last Update Posted:
2017-08-22
First Post:
2006-09-21
Brief Title:
Use of Sugammadex Administered at 5 Minutes After Administration of 12 mgkg Esmeron 194205P05942
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multi-Center Randomized Safety Assessor-Blinded Placebo-Controlled Parallel and Dose Escalating Dose-Finding Trial in Subjects of ASA 1 - 2 to Assess the Safety Efficacy and PK of Sugammadex Administered at 5 Min After Administration of 12 mgkg Esmeron
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the optimal dose of sugammadex when this compound is administered during deep neuromuscular block Sugammadex is administered shortly 5 minutes after administration of a high dose 12 mgkg of the neuromuscular blocking agent rocuronium Under these circumstance the neuromuscular block is deep The safety and pharmacokinetics of sugammadex are also studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 194205 | None | None | None |